ViiV Healthcare reports 0.1% HIV incidence in three-year real-world study of injectable PrEP

The OPERA study confirms the long-term efficacy of long-acting injectable cabotegravir, showing a 0.1% annual HIV infection rate among 1,748 participants. These real-world results reinforce clinical trial data, supporting the drug's role as a primary prevention tool.